Abraham Pinter

Summary

Affiliation: New Jersey
Country: USA

Publications

  1. ncbi request reprint Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci
    Yuxian He
    Laboratory of Retroviral Biology, Public Health Research Institute, Newark, NJ 07103 3535, USA
    J Immunol 169:595-605. 2002
  2. pmc The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection
    Abraham Pinter
    Laboratory of Retroviral Biology, Public Health Research Institute, 225 Warren Street, Newark, NJ 07103, USA
    J Virol 78:5205-15. 2004
  3. pmc HIV-1 subtype C superinfected individuals mount low autologous neutralizing antibody responses prior to intrasubtype superinfection
    Debby Basu
    Immunology and Molecular Pathogenesis Graduate Program, Emory University, Atlanta, GA, USA
    Retrovirology 9:76. 2012
  4. ncbi request reprint Roles of HIV-1 Env variable regions in viral neutralization and vaccine development
    Abraham Pinter
    Public Health Research Institute, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark, NJ 07103 3535, USA
    Curr HIV Res 5:542-53. 2007
  5. pmc The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates
    Abraham Pinter
    Laboratory of Retroviral Biology, Public Health Research Institute, 225 Warren Street, Newark, NJ 07103 3535, USA
    J Virol 79:6909-17. 2005
  6. ncbi request reprint Analysis of the immunogenic properties of a single-chain polypeptide analogue of the HIV-1 gp120-CD4 complex in transgenic mice that produce human immunoglobulins
    Yuxian He
    Laboratory of Retroviral Biology, Public Health Research Institute, 225 Warren Street, Newark, NJ 07103 3506, USA
    Vaccine 21:4421-9. 2003
  7. pmc Characterization of structural features and diversity of variable-region determinants of related quaternary epitopes recognized by human and rhesus macaque monoclonal antibodies possessing unusually potent neutralizing activities
    Chavdar Krachmarov
    Public Health Research Institute, University of Medicine and Dentistry of New Jersey, Newark, NJ 07103, USA
    J Virol 85:10730-40. 2011
  8. pmc Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking
    Chavdar Krachmarov
    Public Health Research Institute, Laboratory of Retroviral Biology, 225 Warren St, Newark, NJ 07103 3535, USA
    J Virol 79:780-90. 2005
  9. pmc Specific sequences commonly found in the V3 domain of HIV-1 subtype C isolates affect the overall conformation of native Env and induce a neutralization-resistant phenotype independent of V1/V2 masking
    Aidy Salomon
    Public Health Research Institute Center, Rutgers University, 225 Warren Street, Newark, NJ 07103, USA
    Virology 448:363-74. 2014
  10. pmc Distinct mechanisms of neutralization by monoclonal antibodies specific for sites in the N-terminal or C-terminal domain of murine leukemia virus SU
    Michael Dominic Burkhart
    Laboratory of Retroviral Biology, Public Health Research Institute, Newark, New Jersey 07103 3535, USA
    J Virol 77:3993-4003. 2003

Research Grants

Collaborators

  • Susan Zolla-Pazner
  • Miroslaw K Gorny
  • Yuxian He
  • S C Kayman
  • James Robinson
  • Shan Lu
  • James B Burritt
  • Seth H Pincus
  • J R Mascola
  • Victoria R Polonis
  • Chavdar Krachmarov
  • Aidy Salomon
  • Zhong Lai
  • Debby Basu
  • William J Honnen
  • Viviana Granados-Gonzalez
  • Royce A Wilkinson
  • C P Krachmarov
  • Michael D Burkhart
  • Michael Tuen
  • Michael Dominic Burkhart
  • Julie Sarlo
  • William Honnen
  • Barry S Zingman
  • Joseph Mulenga
  • Susan A Allen
  • Colleen S Kraft
  • Tianwei Yu
  • Megan K Murphy
  • William Kilembe
  • Carmela Irene
  • Peter T Hraber
  • Elwyn Chomba
  • Patricia J Campbell
  • Cynthia A Derdeyn
  • Eric Hunter
  • Christian Genin
  • Frederic Lucht
  • Nadine Vincent
  • Julien Claret
  • Christiane DeFontaine
  • Willy Berlier
  • Silvio Urcuqui-Inchima
  • Serge Riffard
  • Martin Teintze
  • Charles A Parkos
  • Dustin Slunaker
  • Jody R Evans
  • Jon M Jacobs
  • W J Honnen
  • Pei de Chen
  • Peter C Chien
  • Catarina E Hioe
  • Sandra Cohen
  • Paul D'Agostino
  • Phillipe N Nyambi
  • Maria Luisa Visciano

Detail Information

Publications19

  1. ncbi request reprint Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci
    Yuxian He
    Laboratory of Retroviral Biology, Public Health Research Institute, Newark, NJ 07103 3535, USA
    J Immunol 169:595-605. 2002
    ..These results further our understanding of neutralization targets for primary, R5 HIV-1 viruses and demonstrate the utility of the XenoMouse system for identifying new and interesting epitopes on HIV-1...
  2. pmc The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection
    Abraham Pinter
    Laboratory of Retroviral Biology, Public Health Research Institute, 225 Warren Street, Newark, NJ 07103, USA
    J Virol 78:5205-15. 2004
    ..The rare antibodies capable of neutralizing a broad range of primary isolates thus appeared to be targeted to exceptional epitopes that are not sensitive to V1/V2 domain regulation of neutralization sensitivity...
  3. pmc HIV-1 subtype C superinfected individuals mount low autologous neutralizing antibody responses prior to intrasubtype superinfection
    Debby Basu
    Immunology and Molecular Pathogenesis Graduate Program, Emory University, Atlanta, GA, USA
    Retrovirology 9:76. 2012
    ..We hypothesized that this reflected a blunted NAb response, which may have made these individuals more susceptible to superinfection...
  4. ncbi request reprint Roles of HIV-1 Env variable regions in viral neutralization and vaccine development
    Abraham Pinter
    Public Health Research Institute, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark, NJ 07103 3535, USA
    Curr HIV Res 5:542-53. 2007
    ..Strategies are discussed for using available information to design immunogens capable of exploiting the potential of these regions as vaccine targets...
  5. pmc The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates
    Abraham Pinter
    Laboratory of Retroviral Biology, Public Health Research Institute, 225 Warren Street, Newark, NJ 07103 3535, USA
    J Virol 79:6909-17. 2005
    ....
  6. ncbi request reprint Analysis of the immunogenic properties of a single-chain polypeptide analogue of the HIV-1 gp120-CD4 complex in transgenic mice that produce human immunoglobulins
    Yuxian He
    Laboratory of Retroviral Biology, Public Health Research Institute, 225 Warren Street, Newark, NJ 07103 3506, USA
    Vaccine 21:4421-9. 2003
    ..This property may limit the utility of this chimeric molecule as an HIV-1 vaccine candidate...
  7. pmc Characterization of structural features and diversity of variable-region determinants of related quaternary epitopes recognized by human and rhesus macaque monoclonal antibodies possessing unusually potent neutralizing activities
    Chavdar Krachmarov
    Public Health Research Institute, University of Medicine and Dentistry of New Jersey, Newark, NJ 07103, USA
    J Virol 85:10730-40. 2011
    ....
  8. pmc Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking
    Chavdar Krachmarov
    Public Health Research Institute, Laboratory of Retroviral Biology, 225 Warren St, Newark, NJ 07103 3535, USA
    J Virol 79:780-90. 2005
    ....
  9. pmc Specific sequences commonly found in the V3 domain of HIV-1 subtype C isolates affect the overall conformation of native Env and induce a neutralization-resistant phenotype independent of V1/V2 masking
    Aidy Salomon
    Public Health Research Institute Center, Rutgers University, 225 Warren Street, Newark, NJ 07103, USA
    Virology 448:363-74. 2014
    ....
  10. pmc Distinct mechanisms of neutralization by monoclonal antibodies specific for sites in the N-terminal or C-terminal domain of murine leukemia virus SU
    Michael Dominic Burkhart
    Laboratory of Retroviral Biology, Public Health Research Institute, Newark, New Jersey 07103 3535, USA
    J Virol 77:3993-4003. 2003
    ..These results identify two separate neutralization domains in MuLV SU and suggest a role for the C-terminal domain in a postattachment step necessary for viral fusion...
  11. pmc Involvement of the C-terminal disulfide-bonded loop of murine leukemia virus SU protein in a postbinding step critical for viral entry
    Michael D Burkhart
    Public Health Research Institute, 225 Warren Street, Newark, NJ 07103 3506, USA
    J Virol 79:7868-76. 2005
    ....
  12. pmc Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1
    C P Krachmarov
    The Public Health Research Institute, 255 Warren St, Newark, NJ 07103 3535, USA
    J Virol 80:7127-35. 2006
    ....
  13. ncbi request reprint Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope
    Susan Zolla-Pazner
    New York Veterans Affairs Medical Center, New York, NY 10010, USA
    Virology 372:233-46. 2008
    ..Neutralizing activity was primarily due to V3-specific Abs. The results demonstrate that the immune response can be focused on a neutralizing epitope and show that the anti-V3 Abs induced recognize a diverse set of V3 loops...
  14. ncbi request reprint Peptides selected from a phage display library with an HIV-neutralizing antibody elicit antibodies to HIV gp120 in rabbits, but not to the same epitope
    Royce A Wilkinson
    Departments of Chemistry, Montana State University, Bozeman, Montana 59717 3400, USA
    AIDS Res Hum Retroviruses 23:1416-27. 2007
    ..The antisera also did not compete with CD4 or antibodies to the CD4 binding site for binding to gp120...
  15. pmc The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope
    Miroslaw K Gorny
    Department of Pathology, New York University School of Medicine, New York, New York 10016, USA
    J Virol 78:2394-404. 2004
    ....
  16. pmc Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades
    Miroslaw K Gorny
    Department of Pathology, New York University School of Medicine, New York, NY 10016, USA
    J Virol 76:9035-45. 2002
    ..These studies demonstrate that human MAbs to conformation-sensitive epitopes of V3 display cross-clade reactivity in both binding to native, intact virions and neutralization of primary isolates...
  17. ncbi request reprint Characterization of antibodies that inhibit HIV gp120 antigen processing and presentation
    Michael Tuen
    Department of Pathology, New York University School of Medicine, and Veterans Affairs New York Harbor Healthcare System, New York, NY 10010, USA
    Eur J Immunol 35:2541-51. 2005
    ..The presence of such antibodies could contribute to the dearth of anti-gp120 T helper responses in chronically HIV-1-infected patients...
  18. pmc Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1
    Miroslaw K Gorny
    Department of Pathology, New York University School of Medicine, New York, New York 10016, USA
    J Virol 80:6865-72. 2006
    ....
  19. ncbi request reprint Opposite immune reactivity of serum IgG and secretory IgA to conformational recombinant proteins mimicking V1/V2 domains of three different HIV type 1 subtypes depending on glycosylation
    Viviana Granados-Gonzalez
    Groupe Immunite des Muqueuses et Agents Pathogenes, EA 3064, University of Saint Etienne, Saint Etienne, France
    AIDS Res Hum Retroviruses 24:289-99. 2008
    ....

Research Grants2

  1. Novel HIV Neutralizing Human MAbs from Transgenic Mice
    Abraham Pinter; Fiscal Year: 2006
    ....
  2. ANTIGENIC PROPERTIES OF THE V1/V2 DOMAIN OF HIV-1 GP120
    Abraham Pinter; Fiscal Year: 2010
    ....